DGAP-News: aap Implantate AG / Key word(s): Strategic Company Decision
09.07.2019 / 08:05
The issuer is solely responsible for the content of this announcement.
aap Implantate AG (“aap”) announces that after a detailed analysis to identify cost reduction and efficiency enhancement potentials in the company it will discontinue parts of its standard trauma business at the end of financial year 2019. In future, the company aims to concentrate even stronger on its innovative and promising platform technologies LOQTEQ(R), silver coating and resorbable magnesium implants as well as its comprehensive cannulated screws portfolio.
The distribution of parts of the standard trauma portfolio is to be ceased at the end of financial year 2019. Sales of these products totalled around EUR 0.7 million in financial year 2018. The existing stocks of products of the standard trauma portfolio are to be sold off by the end of the current year. The decision was also taken against the background of the significantly increased regulatory requirements of the new EU Medical Device Regulation (MDR), which lead to considerable personnel and financial expenditures for aap. On the cost side, the discontinuation of parts of the standard trauma portfolio enables aap to avoid not only the expenditures of adapting processes and documents for these products to the increased regulatory requirements of MDR, but also the costs of maintaining their certification in accordance with the new Medical Device Regulation. The company concluded that it makes more economic sense to concentrate on the distribution of its innovative and higher-margin LOQTEQ(R) portfolio as well as its comprehensive range of cannulated screw products. In addition, the further development respectively market approval of the promising platform technologies silver coating and resorbable magnesium implants are to be pushed forward consequently.
About aap Implantate AG
For inquiries please contact: aap Implantate AG, Fabian Franke, Investor Relations, Lorenzweg 5, 12099 Berlin, Germany; Tel.: +49/30/750 19 – 134; Fax.: +49/30/750 19 – 290; email@example.com
09.07.2019 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
|Company:||aap Implantate AG|
|Phone:||+49 (0) 30 75 01 90|
|Fax:||+49 (0) 30 75 01 91 11|
|Listed:||Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange|
|EQS News ID:||838051|
|End of News||DGAP News Service|